MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


0026-895X/03/6402-512-520$20.00
Mol Pharmacol 64:512-520, 2003

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Monczor, F.
Right arrow Articles by Davio, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Monczor, F.
Right arrow Articles by Davio, C.

Tiotidine, a Histamine H2 Receptor Inverse Agonist That Binds with High Affinity to an Inactive G-Protein—Coupled Form of the Receptor. Experimental Support for the Cubic Ternary Complex Model

Federico Monczor, Natalia Fernández, Bibiana Lemos Legnazzi, Maria Eugenia Riveiro, Alberto Baldi, Carina Shayo, and Carlos Davio

Laboratorio de Radioisótopos, Facultad de Farmacia y Bioquímica (F.M., N.F., B.L.L., M.E.R., C.D.) and Departamento de Fisiología, Biología Molecular y Celular, Facultad de Ciencias Exactas y Naturales (C.S.), Universidad de Buenos Aires, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina (F.M., N.F., A.B., C.S., C.D.); and Instituto de Biología y Medicina Experimental, Buenos Aires, Argentina (N.F., A.B., C.S.)

Knowing the importance for research and pharmacological uses of proper ligand classification into agonists, inverse agonists, and antagonists, the aim of this work was to study the behavior of tiotidine, a controversial histamine H2 receptor ligand. We found that tiotidine, described previously as an H2 antagonist, actually behaves as an inverse agonist in U-937 cells, diminishing basal cAMP levels. [3H]Tiotidine showed two binding sites, one with high affinity and low capacity and the other with low affinity and high capacity. The former site disappeared in the presence of guanosine 5'-O-(3-thio)triphosphate, indicating that it belongs to a subset of receptors coupled to G-protein, showing the classic binding profile for an agonist. Considering the occupancy models developed up to now, the only one that explains tiotidine dual behavior is the cubic ternary complex (CTC) model. This model allows G-protein to interact with the receptor even in the inactive state. We showed by theoretical simulations based on the CTC model of dose-response and binding experiments that tiotidine biases the system to a G-protein—coupled form of the receptor that is unable to evoke a response. This theoretical approach was supported by experimental results in which an unrelated G-protein—coupled receptor that also signals through G{alpha}s-protein ({beta}2-adrenoreceptor) was impeded by tiotidine. This interference clearly implies that tiotidine biases the system to G{alpha}s-coupled form of the H2 receptor and turns G{alpha}s-protein less available to interact with {beta}2-adrenoreceptor. These findings not only show that tiotidine is an H2 inverse agonist in U-937 cells but also provide experimental support for the CTC model.


Received January 27, 2003; accepted May 13, 2003

Address correspondence to: Dr. Davio Carlos, Laboratorio de Radioisótopos, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires. Junin 956 PB, 1113, Capital Federal, Argentina. E-mail: cardavio{at}ffyb.uba.ar




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
G. Bongers, K. M. Krueger, T. R. Miller, J. L. Baranowski, B. R. Estvander, D. G. Witte, M. I. Strakhova, P. van Meer, R. A. Bakker, M. D. Cowart, et al.
An 80-Amino Acid Deletion in the Third Intracellular Loop of a Naturally Occurring Human Histamine H3 Isoform Confers Pharmacological Differences and Constitutive Activity
J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 888 - 898.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. M. Amaral, C. Davio, A. Ceballos, G. Salamone, C. Canones, J. Geffner, and M. Vermeulen
Histamine Improves Antigen Uptake and Cross-Presentation by Dendritic Cells
J. Immunol., September 15, 2007; 179(6): 3425 - 3433.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
D.-C. Kim, S.-Y. Choi, S.-H. Kim, B.-S. Yun, I.-D. Yoo, Nanga. R. P. Reddy, H. S. Yoon, and K.-T. Kim
Isoliquiritigenin Selectively Inhibits H2 Histamine Receptor Signaling
Mol. Pharmacol., August 1, 2006; 70(2): 493 - 500.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. R. Dowling, J. M. Willets, D. C. Budd, S. J. Charlton, S. R. Nahorski, and R. A. J. Challiss
A Single Point Mutation (N514Y) in the Human M3 Muscarinic Acetylcholine Receptor Reveals Differences in the Properties of Antagonists: Evidence for Differential Inverse Agonism
J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 1134 - 1142.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
D. M. Perez and S. S. Karnik
Multiple Signaling States of G-Protein-Coupled Receptors
Pharmacol. Rev., June 1, 2005; 57(2): 147 - 161.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. P. Fitzsimons, F. Monczor, N. Fernandez, C. Shayo, and C. Davio
Mepyramine, a Histamine H1 Receptor Inverse Agonist, Binds Preferentially to a G Protein-coupled Form of the Receptor and Sequesters G Protein
J. Biol. Chem., August 13, 2004; 279(33): 34431 - 34439.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics